Following closing, combined company plans to progress Yarrow’s lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating hormone receptor (“TSHR”) antibody for Graves’ disease (“GD”) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback